Similarly, across the LASSO/PLS-DA, 11 antibody features were selectively enriched among vaccinees who developed COVID-19, including both WT and beta RBD-specific IgA, WT or beta-RBD-specific FcγR2A, IgG3, IgM, FcγR2B, IgG1 and IgA to WT or beta VOC S-specific binding antibodies (Fig. 3d). The gene discussed is CD79A; the disease is COVID-19.